Correlation of subjective well-being in schizophrenic patients with gait parameters, expert-rated motor disturbances, and psychopathological status

Pharmacopsychiatry

Volumn 38, Issue 3, 2005, Pages 132-138

  Putzhammer, Albert ^a   Perfahl, M ^a   Pfeiff, L ^a   Hajak, G ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ATYPICAL ANTIPSYCHOTIC AGENT; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; GAIT; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; PRIORITY JOURNAL; RATING SCALE; SCHIZOPHRENIA; STATISTICAL ANALYSIS; SYMPTOMATOLOGY; WELLBEING;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GAIT; HUMANS; LOCOMOTION; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMETRICS; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; STATISTICS; TREATMENT OUTCOME;

EID: 22044440744     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-864125     Document Type: Article

References (40)

1. Allan ER, Sison CE, Alpert M, Connolly B, Crichton J. The relationship between negative symptoms of schizophrenia and extrapyramidal side effects with haloperidol and olanzapine. Psychopharmacol Bull 1998; 34: 71-74
2. Allison DB, Mackell JA, McDonnell DD. The impact of weight gain on quality of life among persons with schizophrenia. Psychiatr Serv 2003; 54: 565-567
3. Awad AG, Voruganti LN, Heslegrave RJ, Hogan TP. Assessment of the patient's subjective experience in acute neuroleptic treatment: implications for compliance and outcome. Int Clin Psychopharmacol 1996; 11 Suppl 2: 55-59
4. Browne S, Garavan J, Gervin M, Roe M, Larkin C, O'Callaghan E. Quality of life in schizophrenia: insight and subjective response to neuroleptics. J Nerv Ment Dis 1998; 186: 74-78
5. Browne S, Roe M, Lane A, Gervin M, Morris M, Kinsella A, Larkin C, Callaghan EO. Quality of life in schizophrenia: relationship to sociodemographic factors, symptomatology and tardive dyskinesia. Acta Psychiatr Scand 1996; 94: 118-124
6. Casey DE. Motor and mental aspects of extra pyramidal syndromes. Int Clin Psychopharmacol 1995; 10 Suppl 3: 105-114
7. Chouinard G, Ross-Chouinard A, Annable L, Jones BD. The Extrapyramidal Symptoms Rating Scale. Can J Neurol Sci 1980; 7: 233-244
8. de Haan L, Lavalaye J, Linszen D, Dingemans PM, Booij J. Subjective experience and striatal dopamine D(2) receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone. Am J Psychiatry 2000; 157: 1019-1020
9. de Haan L, Lavalaye J, van Bruggen M, van Nimwegen L, Booij J, van Amelsvoort T, Linszen D. Subjective experience and dopamine D2 receptor occupancy in patients treated with antipsychotics: clinical implications. Can J Psychiatry 2004; 49: 290-296
10. de Haan L, van Bruggen M, Lavalaye J, Booij J, Dingemans PM, Linszen D. Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study. Am J Psychiatry 2003; 160: 303-309
11. de Haan L, Weisfelt M, Dingemans PM, Linszen DH, Wouters L. Psychometric properties of the Subjective Well-Being Under Neuroleptics scale and the Subjective Deficit Syndrome Scale. Psychopharmacology (Berl) 2002; 162: 24-28
12. Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull 1997; 23: 637-651
13. Garavan J, Browne S, Gervin M, Lane A, Larkin C, O'Callaghan E. Compliance with neuroleptic medication in outpatients with schizophrenia; relationship to subjective response to neuroleptics; attitudes to medication and insight. Compr Psychiatry 1998; 39: 215-219
14. Gerlach J, Larsen EB. Subjective experience and mental side-effects of antipsychotic treatment. Acta Psychiatr Scand Suppl 1999; 395: 113-117
15. Gervin M, Browne S, Garavan J, Roe M, Larkin C, O'Callaghan E. Dysphoric subjective response to neuroleptics in schizophrenia: relationship to extrapyramidal side effects and symptomatology. Eur Psychiatry 1999; 14: 405-409
16. Guy W. Abnormal Involuntary Movement Scale (AIMS). ECDEU Assessment Manual for Psychopharmacology. Public Health Service, Washington, DC: 1976
17. Jaeger J, Bitter I, Czobor P, Volavka J. The measurement of subjective experience in schizophrenia: the Subjective Deficit Syndrome Scale. Compr Psychiatry 1990; 31: 216-226
18. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261-76
19. Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002; 63: 892-909
20. Lambert M, Schimmelmann BG, Karow A, Naber D. Subjective well-being and initial dysphoric reaction under antipsychotic crugs - concepts, measurement and clinical relevance. Pharmacopsychiatry 2003; 36 Suppl 3: S181-190
21. Larsen EB, Gerlach J. Subjective experience of treatment, side-effects, mental state and quality of life in chronic schizophrenic out-patients treated with depot neuroleptics. Acta Psychiatr Acand 1996; 93: 381-388
22. Lewander T. Neuroleptics and the neuroleptic-induced deficit syndrome. Acta Psychiatr Scand Suppl 1994; 380: 8-13
23. Lindstrom LH. Long-term clinical and social outcome studies in schizophrenia in relation to the cognitive and emotional side effects of antipsychotic drugs. Acta Psychiatr Scand Suppl 1994; 380: 74-6, 74-76
24. Loffler W, Kilian R, Toumi M, Angermeyer MC. Schizophrenic patients' subjective reasons for compliance and noncompliance with neuroleptic treatment. Pharmacopsychiatry 2003; 36: 105-112
25. Marder SR. Facilitating compliance with antipsychotic medication. J Clin Psychiatry 1998; 59 Suppl 3: 21-25
26. Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int Clin Psychopharmacol 1995; 10 Suppl 3: 133-8
27. Naber D, Hippius H. Drug treatment of schizophrenia: current concepts. Pharmacopsychiatry 1991; 24: 43-44
28. Naber D, Karow A. Good tolerability equals good results: the patient's perspective. Eur Neuropsychopharmacol 2001; 11 Suppl 4: S391-396
29. Naber D, Karow A, Lambert M. Subjective well-being under neuroleptic treatment and its relevance for compliance. Acta Psychiatr Scand Suppl, 2004: in print
30. Naber D, Moritz S, Lambert M, Pajonk FG, Holzbach R, Mass R, Andresen B, Rajonk F. Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs. Schizophr Res 2001; 50: 79-88
31. Prosser ES, Csernansky JG, Kaplan J, Thiemann S, Becker TJ, Hollister LE. Depression, parkinsonian symptoms, and negative symptoms in schizophrenics treated with neuroleptics. J Nerv Ment Dis 1987; 175: 100-105
32. Putzhammer A, Heindl B, Broll K, Pfeiff L, Perfahl M, Hajak G. Spatial and temporal parameters of gait disturbances in schizophrenic patients. Schizophr Res 2004; 69: 159-166
33. Putzhammer A, Mueller J, Heindl B, Broll K, Pfeiff L, Perfahl M, Hess L, Koch H. Threedimensional ultasonic gait analysis in schizophrenic patients. Psychiatr Praxis 2003; 30 (S2): 110-114
34. Ramaekers JG, Louwerens JW, Muntjewerff ND, Milius H, de Bie A, Rosenzweig P, Patat A, O'Hanlon JF. Psychomotor, Cognitive, extrapyramidal, and affective functions of healthy volunteers during treatment with an atypical (amisulpride) and a classic (haloperidol) antipsychotic. J Clin Psychopharmacol 1999; 19: 209-221
35. Rettenbacher MA, Burns T, Kemmler G, Fleischhacker WW. Schizophrenia: attitudes of patients and professional carers towards the illness and antipsychotic medication. Pharmacopsychiatry 2004; 37: 103-109
36. Ritsner M, Ponizovsky A, Endicott J, Nechamkin Y, Rauchverger B, Silver H, Modai I. The impact of side-effects of antipsychotic agents on life satisfaction of schizophrenia patients: a naturalistic study. Eur Neuropsychopharmacol 2002; 12: 31-38
37. Saunders JB, Inman VT, Eberhardt HD. The major determinants of normal and pathological gait. J Bone Joint Surg 1953; 35A: 543-558
38. Spohn HE, Coyne L. The effect of attention/information processing impairment of tardive dyskinesia and neuroleptics in chronic schizophrenics. Brain Cogn 1993; 23: 28-39
39. Van Putten T. Why do schizophrenic patients refuse to take their drugs? Arch Gen Psychiatry 1974; 31: 67-72
40. Van Putten T, May PR, Marder SR, Wittmann LA. Subjective response to antipsychotic drugs. Arch Gen Psychiatry 1981; 38: 187-190